SCHEDULE 13D/A: Carlyle Group Reduces Stake in NuCana plc Below 5% Threshold

The Carlyle Group and its affiliated entities have disclosed a reduction in their beneficial ownership of NuCana plc's Ordinary Shares to 2.4%, falling below the 5% reporting threshold.

Summary

• The Carlyle Group Inc. and its related entities, including Abingworth LLP and Abingworth Bioventures VII LP, have filed an Amendment No. 2 to their Schedule 13D.
• This amendment reports that as of March 20, 2025, the reporting persons ceased to be beneficial owners of more than five percent of NuCana plc's outstanding Ordinary Shares.
• The current aggregate beneficial ownership by the reporting persons is 3,430,062 Ordinary Shares, representing 2.4% of the class.
• This percentage is based on 142,037,199 Ordinary Shares outstanding as of December 31, 2024, as disclosed in NuCana plc's annual report on Form 20-F filed on March 20, 2025.
• The reported securities include 3,333,333 Ordinary Shares represented by American Depository Shares (ADSs) held by Abingworth Bioventures VII LP, 96,189 Ordinary Shares underlying stock options exercisable within 60 days, and 540 Ordinary Shares represented by ADSs held for the benefit of Abingworth Bioventures VII LP.
• The reporting persons stated they have not effected any transactions with respect to the Ordinary Shares during the past 60 days.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a significant institutional investor reducing its stake below a key threshold, which can be interpreted as a loss of confidence, despite the filing being a routine regulatory disclosure.

Negatives

• The Carlyle Group and its affiliates, a significant institutional investor, have reduced their beneficial ownership in NuCana plc to below the 5% threshold, which could be interpreted by the market as a decrease in investor confidence.

Future Outlook

This filing is a disclosure of past ownership changes and does not contain forward-looking statements or guidance from NuCana plc.

Industry Context

This filing reflects a change in a significant institutional investor's stake in NuCana plc, a biotechnology company. Such changes can influence market perception of a company's prospects within the competitive pharmaceutical and biotech industry, though this specific filing does not provide operational or strategic context.

Stakeholder Impact

• Shareholders: The reduction in a significant institutional investor's stake may lead to concerns about the company's future prospects or valuation, potentially influencing share price.

Key Dates

Recommendation

Keywords

NuCana plc, Carlyle Group, Abingworth, Schedule 13D, SEC filing, beneficial ownership, stake reduction, biotechnology, pharmaceuticals, investment management